Chemical Structure (Levetiracetam 01)
Levetiracetam Tablet, Film Coated, Extended Release
Product Images NDC 69367-332
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 69367-332). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Westminster Pharmaceuticals, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Figure 1 (Levetiracetam 02)
This appears to be a chart or a graph showing the percentage of patients on different doses of immediate-release levetiracetam in a study involving Plaoeho and two other groups. The dosage varied between 1,000 mg/day and 3,000 mg/day. There doesn't seem to be any further information or context to provide.*
Figure 2 (Levetiracetam 03)
Figure 3 (Levetiracetam 04)
This is a graph showing two different treatments for a condition, placebo and immediate-release levetiracetam, with the percentage of patients on the y-axis and the dosage in mg/day on the x-axis. The placebo group had 104 patients and the immediate-release levetiracetam group had 180 patients. The specific data points on the graph are not available.*
Figure 4 (Levetiracetam 05)
This is a chart that shows the percentage of patients under placebo and immediate-release levetiracetam medications based on 10% increment steps from 0 to 45%. The percentage of patients under the placebo is 19.6% while that under the immediate-release levetiracetam is 44.6%.*
Principal Display Panel (500 mg Tablet Bottle Label)
Each film-coated tablet contains 500 mg of levetiracetam, USP. The usual dosage and other information can be found in the accompanying prescribing information. The medication should be stored at controlled room temperature between 68-77°F. It is an extended-release tablet manufactured by ScioGen Pharmaceuticals, Inc. and distributed by Westminster Pharmaceuticals, LLC of Nashville, TN.*
Principal Display Panel (750 mg Tablet Bottle Label)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
